Results 21 to 30 of about 9,646 (180)
Structural basis of leukotriene B4 receptor 1 activation
Nature Communications, 2022 AbstractLeukotriene B4 receptor 1 (BLT1) plays crucial roles in the acute inflammatory responses and is a valuable target for anti-inflammation treatment, however, the mechanism by which leukotriene B4 (LTB4) activates receptor remains unclear. Here, we report the cryo-electron microscopy (cryo-EM) structure of the LTB4 -bound human BLT1 in complex ...
Na Wang +7 more
openaire +3 more sources
Frontiers in Immunology, 2023 Sepsis is defined as a life-threatening dysfunction due to a dysregulated host response to infection. It is a common and complex syndrome and is the leading cause of death in intensive care units. The lungs are most vulnerable to the challenge of sepsis,
Yi Wang +12 more
doaj +1 more source
Regulation of Immune Cells by Eicosanoid Receptors
The Scientific World Journal, 2007 Eicosanoids are potent, bioactive, lipid mediators that regulate important components of the immune response, including defense against infection, ischemia, and injury, as well as instigating and perpetuating autoimmune and inflammatory conditions ...
Nancy D. Kim, Andrew D. Luster
doaj +1 more source
Leukotriene B4 Receptor and the Function of Its Helix 8 [PDF]
Journal of Biological Chemistry, 2005 More than 30 lipid ligands, which express their biological activities through cognate G-protein-coupled receptors (GPCRs), have been reported. Among them, leukotriene B(4) (LTB(4)) is a potent lipid mediator involved in host defense, inflammation, and the immune responses. Two GPCRs for LTB(4) (BLT1 and BLT2) have been cloned and analyzed.
Toshiaki, Okuno +4 more
openaire +2 more sources
Mediators of Inflammation, 2015 Accumulating evidence indicates that leukotriene B4 (LTB4) via its receptors BLT1 and/or BLT2 (BLTRs) could have an important role in regulating infection, tumour progression, inflammation, and autoimmune diseases.
Meng Wang +4 more
doaj +1 more source
, 2014 Recently, there is a progressive growth in new drugs and combinations for treatment of chronic obstructive pulmonary disease (COPD) that, on the one hand, promotes therapeutic opportunities but, on the other hand, impedes the best choice of the drug ...
A. I. Sinopal'nikov +1 more
core +2 more sources
Frontiers in Immunology, 2018 The release of damage-associated molecular patterns, including uridine triphosphate (UTP) and adenosine triphosphate (ATP) to the extracellular milieu is a key component of innate immune response to infection.
Maria Luiza Thorstenberg +6 more
doaj +1 more source
Biochemical and immunological characterization of a novel monoclonal antibody against mouse leukotriene B4 receptor 1. [PDF]
PLoS ONE, 2017 Leukotriene B4 (LTB4) receptor 1 (BLT1) is a G protein-coupled receptor expressed in various leukocyte subsets; however, the precise expression of mouse BLT1 (mBLT1) has not been reported because a mBLT1 monoclonal antibody (mAb) has not been available ...
Fumiyuki Sasaki +7 more
doaj +1 more source
, 2014 Current basic therapy of chronic obstructive pulmonary disease includes inhaled long-acting bronchodilators. This article reviews mechanisms of action of anticholinergic drugs and their potentiation with beta-2-agonists.
V. I. Trofimov +3 more
core +2 more sources